Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TAK-748 in Hemophilia B: NCT04394286 Clinical Landscape Report 2026
16 October 2026
NCT04394286 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bromophenoxyazole Propanoic Acid in Myasthenia Gravis: NL-OMON25316 Clinical Landscape Report 2026
16 October 2026
NL-OMON25316 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Moroctocog alfa in Hemorrhage: NCT04396639 Clinical Landscape Report 2026
16 October 2026
NCT04396639 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bexotegrast in Idiopathic Pulmonary Fibrosis: NCT04396756 Clinical Landscape Report 2026
16 October 2026
NCT04396756 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carbon Dioxide in Brain Diseases: NCT04406818 Clinical Landscape Report 2026
16 October 2026
NCT04406818 clinical landscape for Brain Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nerandomilast in Idiopathic Pulmonary Fibrosis: NCT04419506 Clinical Landscape Report 2026
16 October 2026
NCT04419506 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Voxelotor in Sickle Cell Trait: NCT04400487 Clinical Landscape Report 2026
16 October 2026
NCT04400487 clinical landscape for Sickle Cell Trait: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ET3 gene therapy (Expression Therapeutics) in Hemophilia A: NCT04418414 Clinical Landscape Report 2026
16 October 2026
NCT04418414 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pamrevlumab in Idiopathic Pulmonary Fibrosis: NCT04419558 Clinical Landscape Report 2026
16 October 2026
NCT04419558 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Morphine Sulfate in Idiopathic Pulmonary Fibrosis: NCT04429516 Clinical Landscape Report 2026
16 October 2026
NCT04429516 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Desmopressin Acetate in Nocturnal Enuresis: NCT04420585 Clinical Landscape Report 2026
16 October 2026
NCT04420585 clinical landscape for Nocturnal Enuresis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tofacitinib Citrate in Myasthenia Gravis: NCT04431895 Clinical Landscape Report 2026
16 October 2026
NCT04431895 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.